Mary Mankey, PA
Physician Assistant · Perry, MINPI 1578589453
Payments from drug & device makers
Across 105 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$376
- AstraZeneca$303
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$219
- Lilly USA, LLC$205
- Axsome Therapeutics, Inc.$200
- Pfizer$177
- plus $570 from 13 others
What the payments were for
- Food & beverage$2,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $376 |
| AstraZeneca | 15 | $303 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $219 |
| Lilly USA, LLC | 11 | $205 |
| Axsome Therapeutics, Inc. | 7 | $200 |
| Pfizer | 9 | $177 |
| AbbVie | 6 | $111 |
| Boston Scientific | 3 | $71 |
| Phadia US Inc. | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Exact Sciences | 3 | $53 |
| Bayer | 3 | $48 |
| Amgen | 2 | $37 |
| Novartis | 2 | $32 |
| Abbott | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Philips North America LLC | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,050 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 84 | $61,982 |
| EliquisApixaban | 40 | $49,444 |
| JardianceEmpagliflozin | 34 | $47,237 |
| OzempicSemaglutide | 34 | $44,786 |
| MounjaroTirzepatide | 25 | $28,809 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $15,316 |
| MyrbetriqMirabegron | 13 | $14,949 |
| TrintellixVortioxetine Hydrobromide | 13 | $14,922 |
| RybelsusSemaglutide | 16 | $14,840 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $11,425 |
| Chlorzoxazone | 12 | $10,422 |
| GemtesaVibegron | 17 | $8,900 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $8,663 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,484 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $5,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $376 | $59,62650 claims |
| PfizerEliquis | $177 | $49,44440 claims |
| Lilly USA, LLCMounjaro | $205 | $28,80925 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $14,94913 claims |
| AstraZenecaBreztri Aerosphere | $303 | $8,48414 claims |
| AbbVieSynthroid | $111 | $1,56117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Perry
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.